Retinal nerve fiber layer in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
TDP-43 proteinopathy
amyotrophic lateral sclerosis
frontotemporal lobar degeneration
optical coherence tomography
retinal nerve fibre layer
tauopathy
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
06
2022
accepted:
31
08
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
epublish
Résumé
Tauopathy and transactive response DNA binding protein 43 (TDP-43) proteinopathy are associated with neurodegenerative diseases. These proteinopathies are difficult to detect Prospective, multi-centre, observational study. pRNFL and macular SD-OCT images were acquired in both eyes of each participant using Heidelberg Spectralis SD-OCT. Global and pRNFL thickness in 6 sectors were analyzed, as well as macular thickness in a central 1 mm diameter zone and 4 surrounding sectors. Linear mixed model methods adjusting for baseline differences between groups were used to compare the two groups with respect to pRNFL and macular thickness. A significant difference was found in mean pRNFL thickness between groups, with the TDP-43 group ( The finding that the temporal pRNFL in the TDP-43 group was on average 15.46 μm thinner could potentially have clinical significance. Future work with larger sample sizes, longitudinal studies, and at the level of retinal sublayers will help to determine the utility of SD-OCT to differentiate between these two proteinopathies.
Identifiants
pubmed: 36278002
doi: 10.3389/fnins.2022.964715
pmc: PMC9583385
doi:
Types de publication
Journal Article
Langues
eng
Pagination
964715Investigateurs
Sabrina Adamo
(S)
Stephen Arnott
(S)
Rob Bartha
(R)
Derek Beaton
(D)
Courtney Berezuk
(C)
Alanna Black
(A)
Alisia Bonnick
(A)
David Breen
(D)
Don Brien
(D)
Susan Bronskill
(S)
Dennis Bulman
(D)
Leanne Casaubon
(L)
Ying Chen
(Y)
Marvin Chum
(M)
Brian Coe
(B)
Ben Cornish
(B)
Jane Lawrence Dewar
(JL)
Roger A Dixon
(RA)
Sherif El-Defrawy
(S)
Sali Mk Farhan
(SM)
Frederico Faria
(F)
Julia Fraser
(J)
Mahdi Ghani
(M)
Barry Greenberg
(B)
Hassan Haddad
(H)
Wendy Hatch
(W)
Melissa Holmes
(M)
Chris Hudson
(C)
Peter Kleinstiver
(P)
Donna Kwan
(D)
Elena Leontieva
(E)
Brian Levine
(B)
Wendy Lou
(W)
Efrem D Mandelcorn
(ED)
Ed Margolin
(E)
Connie Marras
(C)
Bill McIlroy
(B)
Paula McLaughlin
(P)
Manuel Montero Odasso
(MM)
Doug Munoz
(D)
David Munoz
(D)
Nuwan Nanayakkara
(N)
J B Orange
(JB)
Miracle Ozzoude
(M)
Alicia Peltsch
(A)
Pradeep Raamana
(P)
Joel Ramirez
(J)
Natalie Rashkovan
(N)
Angela Roberts
(A)
Yanina Sarquis Adamson
(YS)
Christopher Scott
(C)
Michael Strong
(M)
Stephen Strothers
(S)
Sujeevini Sujanthan
(S)
Kelly M Sunderland
(KM)
Sean Symons
(S)
Faryan Tayyari
(F)
Athena Theyers
(A)
Angela Troyer
(A)
Abiramy Uthirakumaran
(A)
Karen Van Ooteghem
(KV)
John Woulfe
(J)
Mojdeh Zamyadi
(M)
Guangyong Gy Zou
(GG)
Informations de copyright
Copyright © 2022 Wong, Hudson, Snook, Tayyari, Jung, Binns, Samet, Cheng, Balian, Mandelcorn, Margolin, Finger, Black, Tang-Wai, Zinman, Tan, Lou, Masellis, Abrahao, Frank, Beaton, Sunderland, Arnott, ONDRI Investigators, Tartaglia and Hatch.
Déclaration de conflit d'intérêts
EM received honoraria for speaking engagements from Bayer and Novartis, none of which are relevant to this study. SB was a consultant for Roche and Pfizer. SB obtained funding and has funding pending (through institutions) from GE Healthcare, Eli Lilly, Biogen Idec, Genentech, Optina, Roche, and Novartis. SA was a consultant for Indoc Research Canada (not relevant to this study). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Neurol. 2013 Aug;20(8):1170-6
pubmed: 23582075
Transl Vis Sci Technol. 2019 Sep 11;8(5):6
pubmed: 31588371
Ann Neurol. 2013 Jul;74(1):20-38
pubmed: 23686809
Acta Neuropathol. 2015 Apr;129(4):469-91
pubmed: 25549971
Neuroscience. 2018 Oct 15;390:1-11
pubmed: 30134203
Front Neurosci. 2020 Sep 25;14:566858
pubmed: 33071739
Front Neurol. 2017 Dec 19;8:701
pubmed: 29312125
Nature. 1989 Oct 19;341(6243):643-6
pubmed: 2797190
Mol Neurodegener. 2020 Jun 1;15(1):31
pubmed: 32487123
Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8095-103
pubmed: 24194190
PLoS One. 2017 Sep 25;12(9):e0185242
pubmed: 28945811
J Mol Neurosci. 2011 Nov;45(3):330-5
pubmed: 21584654
Sci Rep. 2017 Jul 13;7(1):5357
pubmed: 28706282
Front Genet. 2020 Sep 02;11:562758
pubmed: 32983232
J Neuropathol Exp Neurol. 2005 Aug;64(8):730-9
pubmed: 16106222
J Neurol. 2018 Jul;265(7):1557-1562
pubmed: 29713825
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurology. 2017 Oct 10;89(15):1604-1611
pubmed: 28887373
J Exp Med. 2014 Sep 22;211(10):1937-45
pubmed: 25155018
J Neuroophthalmol. 2013 Mar;33(1):62-5
pubmed: 23100041
J Neuroophthalmol. 2018 Jun;38(2):151-155
pubmed: 29240574
Neurology. 2003 Aug 12;61(3):349-54
pubmed: 12913196
Brain Sci. 2019 Nov 24;9(12):
pubmed: 31771268
J Alzheimers Dis. 2017;56(3):1101-1107
pubmed: 28106555
Br J Ophthalmol. 2009 Nov;93(11):1448-52
pubmed: 19019921
Ann Clin Transl Neurol. 2014 Apr;1(4):290-7
pubmed: 25590041
Rev Neurol (Paris). 2013 Oct;169(10):793-8
pubmed: 24011641
Can J Neurol Sci. 2017 Mar;44(2):196-202
pubmed: 28003035
Neurol Clin. 2017 May;35(2):339-374
pubmed: 28410663
Front Neurosci. 2019 Apr 04;13:298
pubmed: 31019447
J Glaucoma. 2015 Jan;24(1):45-50
pubmed: 23429636